Home/Federal Circuit/Gilead Sciences, Inc. v. Merck & Co., Inc.

Gilead Sciences, Inc. v. Merck & Co., Inc.

Procedural entryThis page is a short order in Gilead Sciences, Inc. v. Merck & Co., Inc.. Read the opinion of the Court — 888 F.3d 1231 →
Court of Appeals for the Federal Circuit·Decided April 26, 2018·No. 16-2302·Published

Opinion

United States Court of Appeals for the Federal Circuit ______________________

April 26, 2018

ERRATUM ______________________

Appeal Nos. 2016-2302, 2016-2615

GILEAD SCIENCES, INC., Plaintiff-Cross-Appellant

v.

MERCK & CO., INC., MERCK SHARP & DOHME CORP., ISIS PHARMACEUTICALS, INC., Defendants-Appellants

Decided: April 25, 2018 Precedential Opinion _____________________

Please make the following change: On page 2, line 21, “Solvadi®” is changed to “Sovaldi®”

Free access — add to your briefcase to read the full text and ask questions with AI

Gilead Sciences, Inc. v. Merck & Co., Inc., (Fed. Cir. 2018).

Gilead Sciences, Inc. v. Merck & Co., Inc. (Gilead Sciences, Inc. v. Merck & Co., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.